Biomea Fusion to announce Phase II trial results for icovamenib in type 2 diabetes.

From GlobeNewswire: 2024-12-16 18:15:01

Biomea Fusion, Inc. will present topline results from its Phase II trial of icovamenib for type 2 diabetes on December 17, 2024, at 8:00 am EST. The webcast will be available on the company’s website, and a replay will be archived after the event. Biomea Fusion focuses on developing oral covalent small molecules for diabetes, obesity, and genetically defined cancers to maximize clinical benefit for patients. They aim to have a significant impact on disease treatment and ultimately cure patients. Contact COO & President Ramses Erdtmann for more information at [email protected].



Read more at GlobeNewswire: Biomea Fusion to Host Conference Call to Announce Topline